Technology & Innovation Centre, 99 George, Street, Glasgow G1 1RD | info@screenin3d.com | +44 (0) 141 444 7368

ScreenIn3D utilises proprietary and unique UpScale3D lab-on-a- chip technology and Assess3D image analysis software to create cost-effective, high-quality, large-throughput and data-rich assays, accelerating the development of new drug candidates. OUR TECHNOLOGY
PLATFORM:
how it works

RESULTS

noun-stopwatch-8075678

FASTER

noun-coin-8038811

LESS COST

noun-data-on-screen-4431543

BETTER DATA

UNIQUE

noun-add-3523383

COMBINE

noun-team-7477836

PERSONALISE

noun-team-7969548

STRATIFY

FEATURES

noun-capsule-6113735

DRUG PERFUSION

noun-pipes-7701542

NO TUBING

noun-play-3205303

PLUG & PLAY

Our platform, originally developed for oncology drug screening, supports 3D culture of a variety of cell types and disease models.

HOW IT WORKS

3D complex disease model generation

Single cell or preformed 3D model suspensions are injected into our platform to grow into spheroids, organoids, or multi-cell 3D models. Using a few thousand cells, hundreds of 3D models are generated.

Drug delivery and screening

Compounds are delivered on your custom schedule alone or in combination, implementing multiple therapy modalities. Additional cells or drugs can be injected on demand without disturbing the culture.

Test drugs like in the human body

Our proprietary technology mimics human physiology without the need for tubing or flow equipment, allowing for unparalleled scalability in large throughput, automated, standardized assays.

Why 3D and human tissue?

Testing drugs on patient-derived 3D models significantly increase the chance of finding drugs that are effective in clinical settings

Why using UpScale3D platform?

Our technology enables a vast number of combination therapies to be tested on patient-derived samples, achieving at least 20 times more data than standard methods.

Why now?

Following the Modernization Act 2.0 in 2023, worldwide agencies plan to phase out animal testing by 2035. Lab-on-a-chip technologies and organoids are ideally suited to offer valuable replacement for drug discovery and drug approval